risedronic acid has been researched along with Bone Loss, Perimenopausal in 379 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 9.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 9.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 9.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 8.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 8.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| " We present a case of acute polyarthritis after administration of alendronate and risedronate in a 52-year-old woman." | 7.83 | Alendronate- and risedronate-induced acute polyarthritis. ( Uğurlar, M, 2016) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 7.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "To assess the effectiveness and safety of denosumab (Prolia®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW)." | 5.41 | The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. ( Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T, 2023) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 5.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 5.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "This study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis." | 5.16 | Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. ( Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G, 2012) |
| "We performed a randomized, double-blind, prospective, 16-week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis." | 5.15 | Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. ( Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK, 2011) |
| "The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia." | 5.14 | Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. ( Stepan, JJ; Zikan, V, 2009) |
| "PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole." | 5.14 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 5.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, or alendronate, a primary amino bisphosphonate, in healthy postmenopausal women stratified by Helicobacter pylori status." | 5.10 | 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. ( Blank, MA; Hunt, RH; Lanza, FL; Li, Z; Marshall, JK; Provenza, JM; Royer, MG; Thomson, AB, 2002) |
| " This study compared the incidence of gastric ulcers after treatment with risedronate, a pyridinyl bisphosphonate, and alendronate, a primary amino bisphosphonate." | 5.09 | Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. ( Blank, MA; Hunt, RH; Lanza, FL; Provenza, JM; Thomson, AB, 2000) |
| "Fifty-three white women, aged 36 to 55 years, with breast cancer and artificially induced menopause were stratified according to prior tamoxifen use." | 5.08 | Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. ( Balena, R; Bremond, A; Confravreux, E; Delmas, PD; Hardouin, C; Hardy, P, 1997) |
| "The purpose of this paper is to discuss the effects of antifracture drugs on postmenopausal, male and glucocorticoid-induced osteoporosis, focussing on the efficacy and safety of alendronate and risedronate." | 4.84 | Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. ( Iwamoto, J; Sato, Y; Takeda, T, 2007) |
| " Alendronate and risedronate are the two most widely used compounds in the treatment of postmenopausal osteoporosis." | 4.83 | Bisphosphonates. ( Botsis, D; Christodoulakos, G; Lambrinoudaki, I, 2006) |
| "Studies of risedronate were obtained from the MEDLINE database (1966 to the present) of references using risedronate, risedronic acid, osteoporosis, and human subject as keywords." | 4.81 | Risedronate: a clinical review. ( Crandall, C, 2001) |
| "According to the data of a fracture intervention trial, in women aged 55-80 years with vertebral fractures or osteoporosis diagnosed by bone mineral density measurement, treatment with the bisphosphonate alendronate prevented hip fractures with numbers-needed-to-treat within 5 years of treatment of 46 and 66, respectively." | 4.81 | [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. ( Netelenbos, JC, 2001) |
| "Alendronate and risedronate, the two oral bisphosphonates approved in the United States for preventing and treating osteoporosis, have never been compared in direct head-to-head trials, but they appear to have similar pharmacokinetics, drug interactions, adverse effect profiles, and efficacy." | 4.81 | Role of alendronate and risedronate in preventing and treating osteoporosis. ( Leonard, M; Licata, AA; Peters, ML, 2001) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "We believe that the continuous use of alendronate and risedronate for 10 years could be an option for the treatment of postmenopausal osteoporosis patients." | 3.96 | Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. ( Iba, K; Sonoda, T; Takada, J; Yamashita, T, 2020) |
| "Retrospective single-center cohort study of osteoporosis patients treated with alendronate or risedronate for at least 2 years and then discontinued their bisphosphonate for a drug holiday." | 3.83 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. ( Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH, 2016) |
| " Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8." | 3.83 | Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal. ( Borgström, F; da Silva, JA; Kanis, JA; Lourenço, Ó; Marques, A; Ortsäter, G, 2016) |
| " We present a case of acute polyarthritis after administration of alendronate and risedronate in a 52-year-old woman." | 3.83 | Alendronate- and risedronate-induced acute polyarthritis. ( Uğurlar, M, 2016) |
| " We report a case of BRONJ in a patient following six years of oral BP administration for the management of osteoporosis, complicated by four years of prednisone therapy for pulmonary fibrosis." | 3.81 | Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis. ( Reiss, S; Sultan, D, 2015) |
| "Compared with use of alendronate/risedronate, use of strontium was not associated with significantly increased risk of acute coronary syndrome (rate per 1000 person-years 5." | 3.80 | Use of strontium ranelate and risk of acute coronary syndrome: cohort study. ( Hviid, A; Pasternak, B; Svanström, H, 2014) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 3.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "The findings supported the diagnosis of an acute exacerbation of a chronic risedronat-induced esophagitis caused by clindamycin." | 3.75 | [Acute exacerbation of a chronic esophagitis]. ( Göke, B; Ihrler, S; Kolligs, FT; Winkler-Budenhofer, UC, 2009) |
| "We studied 26,636 new users of an osteoporosis medication (alendronate, calcitonin, estrogen, raloxifene, or risedronate) who were age 65 or older and had an extended lapse in refill compliance, defined as a period of at least 60 days after the completion of one prescription in which no refill for any osteoporosis medication was obtained." | 3.74 | Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. ( Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH, 2007) |
| " In addition, we looked at benefit and harm comparisons between different dosage regimens for risedronate and between risedronate and other anti-osteoporotic drugs." | 2.82 | Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. ( Hsieh, SC; Liu, W; Peterson, J; Tugwell, P; Wells, GA; Zheng, C, 2022) |
| "For many patients, adhering to postmenopausal osteoporosis treatment is a challenge." | 2.80 | Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. ( Agodoa, I; Bonnick, S; Brown, JP; Ferreira, I; Ho, PR; Palacios, S; Van den Bergh, JP, 2015) |
| "The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1)." | 2.80 | Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study. ( Lorenc, R; Oral, A, 2015) |
| " The subjects' bone mineral densities (BMDs), bone turnover markers (P1NP and β-CTX), new vertebral fractures, and adverse events were assessed at baseline and during the treatments." | 2.80 | The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data. ( Chen, DC; Fu, WZ; Gu, JM; He, JW; Hu, WW; Hu, YQ; Jin, XL; Lin, H; Liu, YJ; Tang, H; Wang, C; Wang, L; Xia, WB; Yue, H; Zhang, H; Zhang, ZL, 2015) |
| " We aimed to evaluate the effects of risedronate alone or combined with vitamin K2 on serum ucOC, OC, and incidence of vertebral fractures in elderly osteoporotic patients." | 2.79 | Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. ( Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y, 2014) |
| " Overall and serious adverse events were similar between groups." | 2.79 | Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. ( Brown, JP; Fahrleitner-Pammer, A; Ferreira, I; Hawkins, F; Ho, PR; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Roux, C; Siddhanti, S; Stone, M; Wagman, RB; Wark, JD; Zillikens, MC, 2014) |
| " Bone mineral density (BMD), bone turnover markers, new vertebral fractures, and adverse events were evaluated." | 2.78 | Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. ( Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2013) |
| " Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance." | 2.78 | Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. ( Balske, A; Burgio, DE; McClung, MR; Recker, RR; Wenderoth, D, 2013) |
| " This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis." | 2.78 | A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. ( Balske, AM; Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, R; Tlustochowicz, W; Zanchetta, JR, 2013) |
| "New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients." | 2.77 | Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. ( Aoyagi, K; Chiba, K; Doiguchi, Y; Furuichi, I; Hashikawa, T; Motokawa, S; Norimatsu, T; Osaki, M; Shindo, H; Tatsuki, K, 2012) |
| " Bone mineral density (BMD), bone turnover markers (BTMs), fractures, and adverse events were evaluated." | 2.77 | Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. ( Balske, A; Benhamou, CL; Bolognese, MA; Brown, JP; Burgio, DE; McClung, MR; McCullough, LK; Miller, PD; Recker, RR; Sarley, J; Zanchetta, J, 2012) |
| " These results suggested that ECT in combination with risedronate was more effective than risedronate alone for reducing back pain in postmenopausal women with osteoporosis." | 2.77 | Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. ( Iwamoto, J; Takakuwa, M, 2012) |
| "Two studies in postmenopausal women with osteoporosis provide information about the efficacy and safety of dosing oral risedronate 5 mg daily at a time other than before breakfast (i." | 2.74 | Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. ( Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B, 2009) |
| " Once-monthly dosing options might increase treatment compliance and persistence." | 2.74 | Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. ( Beary, JF; Brown, JP; Burgio, DE; Darbie, LM; Matzkin, E; Racewicz, AJ; Ste-Marie, LG, 2009) |
| " Despite serum isoflavone profiles indicating bioavailability of the phytoestrogens, only soy isoflavones from the cotyledon and germ significantly decreased net bone resorption by 9% (P = 0." | 2.74 | Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. ( Barnes, S; Boris, ME; Jackson, GS; Martin, BR; McCabe, GP; McCabe, LD; Nolan, JR; Peacock, M; Reinwald, S; Weaver, CM, 2009) |
| " Based on these results, the effects of risedronate 35 mg once a week are similar in efficacy to daily dosing and may lead less adverse events than once-a-month dose." | 2.74 | Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. ( Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S, 2009) |
| "Alendronate was randomly prescribed for 41 patients and risedronate were prescribed for 43 patients." | 2.73 | Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. ( Iizuka, T; Matsukawa, M, 2008) |
| " Inconvenient dosing was reported as a primary reason for discontinuation due to stopping or changing treatment in 19 (6." | 2.73 | Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. ( Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D, 2007) |
| "The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture." | 2.73 | [The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. ( Altintaş, F; Beyzadeoğlu, T; Eren, A; Güven, M; Ozkut, AT, 2007) |
| "Six postmenopausal women with diagnosed osteopenia/osteoporosis received a single oral dose of 100 nCi 41Ca for skeleton labeling." | 2.73 | Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. ( Denk, E; Fattinger, K; Häuselmann, HJ; Hillegonds, D; Hurrell, RF; Kraenzlin, M; Vogel, J; Walczyk, T, 2007) |
| " Bone mineral density, bone turnover markers, fractures, and adverse events were evaluated." | 2.73 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. ( Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR, 2008) |
| " Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule." | 2.73 | Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. ( Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J, 2008) |
| "One of the most widely used bone resorption markers is cross-linked N-terminal telopeptides (NTX)." | 2.73 | Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. ( Abe, Y; Fukao, A; Ishikawa, H, 2008) |
| "Our goal was to examine prevention of breast cancer-related bone loss in this cohort." | 2.73 | Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. ( Bhattacharya, R; Brufsky, A; Greenspan, SL; Lembersky, BC; Perera, S; Sereika, SM; Vogel, VG; Vujevich, KT, 2008) |
| "To determine the clinical recommended dosage regimen of risedronate for the treatment of involutional osteoporosis in Japanese patients, dose-response relationships for the efficacy and safety of this drug were investigated using a multi-center, randomized, double-blind, parallel group comparative design with four dose levels of risedronate (placebo, 1 mg, 2." | 2.71 | A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). ( Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K, 2003) |
| " To assess the anti-fracture efficacy of this new regimen, we have analyzed the fracture data collected in an active controlled study of risedronate dosing regimens (the Once-a-Week study) using matched historical control data from previous placebo-controlled trials." | 2.71 | Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. ( Brown, J; Kasibhatla, C; Li, Z; Lindsay, R; Watts, NB, 2003) |
| "Greater decreases in bone resorption markers were associated with greater decreases in vertebral (and nonvertebral) fractures." | 2.71 | Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. ( Barton, I; Chines, A; Delmas, PD; Eastell, R; Garnero, P; Hannon, RA, 2003) |
| "To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis." | 2.71 | Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. ( Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003) |
| "The efficacy and tolerability of risedronate once-a-week dosing (35 and 50mg) were compared with risedronate daily dosing (5mg) in a 2-year study in women with osteoporosis." | 2.71 | Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. ( Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB, 2004) |
| " The changes were compared in bone mineral density (BMD), bone metabolism markers and adverse events after 12 months oral administration of risedronate sodium." | 2.71 | Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis. ( Chen, L; Deng, X; Li, Y; Zhang, Z, 2005) |
| "Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal." | 2.71 | Monitoring of Risedronate by biochemical bone markers in clinical practice. ( Bunyaratavej, N, 2005) |
| " The time course of changes in PTH levels following cessation of dosing was unaffected by calcium supplementation." | 2.70 | Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. ( Collette, J; Eastell, R; Ethgen, D; Reginster, JY; Roumagnac, I; Russell, RG; Zegels, B, 2001) |
| "Gastric ulcers were noted in eight subjects in the aspirin group, one in the placebo group, and none in the risedronate group (P=0." | 2.69 | Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. ( Blank, MA; Krajewski, SA; Lanza, FL; Li, Z; Rack, MF, 2000) |
| " In these studies another formulation of the drug and other dosing instructions are used." | 2.68 | A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. ( Christiansen, C; Clemmesen, B; Ravn, P; Reginster, JY; Taquet, AN; Zegels, B, 1997) |
| " The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35 mg to be taken weekly, before or after breakfast." | 2.52 | Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. ( Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG, 2015) |
| "A meta-analysis of spine BMD dose-response relationships for alendronate, risedronate, and ibandronate was performed." | 2.49 | A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. ( Yates, J, 2013) |
| "Postmenopausal osteoporosis is a chronic disease requiring treatment that balances long-term fracture efficacy against risk." | 2.48 | Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). ( Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R, 2012) |
| " Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important." | 2.47 | Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. ( Glendenning, P; Inderjeeth, CA; Lee, S, 2011) |
| " Also reviewed are results of "bridging" studies designed to demonstrate the comparable efficacy of less frequent dosing regimens to increase bone mineral density and to reduce bone turnover." | 2.45 | Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. ( Bilezikian, JP, 2009) |
| " The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed." | 2.45 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. ( Rackoff, P, 2009) |
| " Current dosing schedules are often inconvenient or impractical for patients." | 2.44 | Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. ( Díaz-Curiel, M; Moro-Alvarez, MJ, 2008) |
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| " Risedronate was safe and effective in osteoporotic women with mild, moderate, or severe age-related renal impairment." | 2.43 | Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. ( Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C, 2005) |
| "Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens." | 2.43 | Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006) |
| " RCTs have demonstrated that the incidence of gastrointestinal tract adverse events in postmenopausal osteoporotic women treated with bisphosphonates and placebo are similar, and also the long-term efficacy and safety of alendronate and risedronate." | 2.43 | Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T, 2006) |
| "In contrast to postmenopausal osteoporosis, the overriding objective in senior citizens older than 75 years is to avoid fractures of the hip, which are associated with a high mortality rate." | 2.43 | [Osteoporosis in the elderly--diagnosis and treatment]. ( Gärtner, R, 2005) |
| "Osteopenia is a progressive condition that places patients at risk for increased morbidity and mortality if untreated." | 2.42 | Identifying the osteopenic patient and preventing worsening of the disease. ( Derman, R, 2003) |
| "Alendronate has demonstrated significant reductions in vertebral and nonvertebral fracture risk after 3 years." | 2.42 | An approach to postmenopausal osteoporosis treatment: a case study review. ( Kessenich, C, 2003) |
| "The objective of this review is to present the clinical profiles of the once-weekly and once-daily dosing formulations of alendronate and risedronate, the 2 bisphosphonates currently available in the United States for the prevention and treatment of postmenopausal osteoporosis." | 2.42 | Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. ( Emkey, R, 2004) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.42 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "Postmenopausal osteoporosis is a widespread condition that affects the physical and emotional well-being of millions of women worldwide." | 2.41 | Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials. ( Watts, NB, 2001) |
| "Key search terms were risedronate, postmenopausal osteoporosis, and fractures." | 2.41 | Risedronate for the prevention of fractures in postmenopausal osteoporosis. ( Nip, CS; Sickels, JM, 2002) |
| " Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy." | 1.72 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. ( Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022) |
| "The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France." | 1.51 | Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. ( Hiligsmann, M; Reginster, JY, 2019) |
| " In the zoledronate group, mean PINP 6 months post-FRAME was 23 ± 4 µg/L and at 12 months it was 47 ± 8 µg/L, suggesting that repeat zoledronate dosing is needed at 1 year to maintain the BMD gains." | 1.48 | Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates. ( Horne, AM; Mihov, B; Reid, IR, 2018) |
| "The frequency distribution of the bone resorption marker urinary deoxypyridinoline crosslinks (uDPD), was obtained retrospectively from 211 osteoporotic women attended at an academic hospital endocrine clinic, treated for >2 years with oral bisphosphonates." | 1.46 | BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD. ( Liel, Y; Plakht, Y; Tailakh, MA, 2017) |
| "This retrospective, observational study assessed 2-year persistence and compliance by treatment, route of administration, and dosing frequency in postmenopausal women initiating a new osteoporosis therapy." | 1.46 | Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. ( Barron, R; Durden, E; Juneau, P; Lopez-Gonzalez, L; Pinto, L, 2017) |
| "We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population." | 1.39 | Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013) |
| "Women with postmenopausal osteoporosis, assigned to receive either TPTD (TPTD group, n = 13) or RIS (RIS group, n = 36) for 6 months, and non-osteoporotic early postmenopausal women (NOEP group, n = 13) were recruited." | 1.38 | Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. ( Anastasilakis, AD; Bratengeier, C; Papatheodorou, A; Polyzos, SA; Terpos, E; Woloszczuk, W, 2012) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| " Intravenous ibandronate suppressed serum CTX levels to a significantly greater degree at 7 days after the second dosing (0." | 1.38 | Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. ( Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH, 2012) |
| "Thirteen Japanese type 2 diabetes postmenopausal women with newly diagnosed osteoporosis (osteoporosis group) and 13 age- and weight-matched diabetic women with normal bone mineral density (control group) were enrolled in this 1-year prospective study." | 1.36 | Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis. ( Hayashi, K; Kanazawa, I; Shimizu, T; Sugimoto, T; Takase, H; Yamaguchi, T, 2010) |
| "We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13." | 1.35 | Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 1.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| "The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly." | 1.35 | Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. ( Möller, G; Ringe, JD, 2009) |
| " The effect of patient age, prescriber, initial dosing regimen, gastrointestinal adverse events, co-medication and fractures on non-compliance was investigated." | 1.35 | Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. ( Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 1.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| " Reducing oral bisphosphonate dosing frequency is one measure available to increase therapy convenience and practicality, with the hope of improving compliance and persistence." | 1.33 | Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. ( Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A, 2005) |
| "Patients preferred a weekly dosing regimen with proven vertebral and non-vertebral fracture efficacy." | 1.33 | Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. ( Gold, DT; Safi, W; Trinh, H, 2006) |
| " This dosage was well tolerated with a low incidence of GI side effects." | 1.32 | Bone density changes with once weekly risedronate in postmenopausal women. ( Delaney, MF; Hurwitz, S; LeBoff, MS; Shaw, J, 2003) |
| "The purpose of this study was to determine compliance with dosing instructions, and the prevalence of possible adverse events, when risedronate is used in clinical practice." | 1.32 | Tolerability and compliance with risedronate in clinical practice. ( Hamilton, B; McCoy, K; Taggart, H, 2003) |
| "Hip fractures are the most costly and best-documented complication of osteoporosis." | 1.32 | Health-economic comparison of three recommended drugs for the treatment of osteoporosis. ( Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A, 2004) |
| "Up to 80-90% of patients with treatment-requiring osteoporosis are not receiving specific treatment." | 1.31 | [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate]. ( Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (3.96) | 18.2507 |
| 2000's | 238 (62.80) | 29.6817 |
| 2010's | 106 (27.97) | 24.3611 |
| 2020's | 20 (5.28) | 2.80 |
| Authors | Studies |
|---|---|
| Thomasius, F | 2 |
| Palacios, S | 2 |
| Alam, A | 1 |
| Boolell, M | 3 |
| Vekeman, F | 2 |
| Gauthier, G | 1 |
| Waltman, N | 1 |
| Kupzyk, KA | 2 |
| Flores, LE | 1 |
| Mack, LR | 2 |
| Lappe, JM | 2 |
| Bilek, LD | 2 |
| Hayes, KN | 1 |
| Brown, KA | 1 |
| Cheung, AM | 1 |
| Kim, SA | 1 |
| Juurlink, DN | 1 |
| Cadarette, SM | 2 |
| Shen, J | 1 |
| Ke, Z | 1 |
| Dong, S | 1 |
| Lv, M | 1 |
| Yuan, Y | 1 |
| Song, L | 1 |
| Wu, K | 1 |
| Xu, K | 1 |
| Hu, Y | 1 |
| Goeree, R | 3 |
| Burke, N | 1 |
| Jobin, M | 1 |
| Brown, JP | 8 |
| Lawrence, D | 1 |
| Stollenwerk, B | 1 |
| Willems, D | 1 |
| Johnson, B | 1 |
| Wells, GA | 1 |
| Hsieh, SC | 1 |
| Zheng, C | 1 |
| Peterson, J | 2 |
| Tugwell, P | 4 |
| Liu, W | 1 |
| González Macías, J | 1 |
| Olmos Martínez, JM | 1 |
| Tutaworn, T | 1 |
| Nieves, JW | 1 |
| Wang, Z | 1 |
| Levin, JE | 1 |
| Yoo, JE | 1 |
| Lane, JM | 1 |
| Pedersen, AB | 1 |
| Risbo, N | 1 |
| Kafatos, G | 1 |
| Neasham, D | 1 |
| O'Kelly, J | 1 |
| Ehrenstein, V | 1 |
| Mendes, D | 1 |
| Penedones, A | 1 |
| Alves, C | 1 |
| Oliveira, T | 1 |
| Donato, A | 1 |
| Batel-Marques, F | 1 |
| Eisman, JA | 2 |
| Cortet, B | 2 |
| Ionescu-Ittu, R | 1 |
| Heroux, J | 1 |
| Moshi, MR | 1 |
| Nicolopoulos, K | 1 |
| Stringer, D | 1 |
| Ma, N | 1 |
| Jenal, M | 1 |
| Vreugdenburg, T | 1 |
| Casado, E | 3 |
| Rosas, J | 1 |
| Rubio-Terrés, C | 1 |
| Rubio-Rodríguez, D | 1 |
| Arístegui, I | 1 |
| Kendler, DL | 8 |
| Marin, F | 5 |
| Geusens, P | 11 |
| López-Romero, P | 4 |
| Lespessailles, E | 5 |
| Body, JJ | 4 |
| Minisola, S | 8 |
| Iba, K | 4 |
| Takada, J | 4 |
| Sonoda, T | 1 |
| Yamashita, T | 4 |
| Deng, Y | 1 |
| Li, L | 1 |
| Li, C | 1 |
| Wang, F | 1 |
| Qu, Y | 1 |
| McClung, MR | 13 |
| Ebetino, FH | 2 |
| Zerbini, CAF | 4 |
| Möricke, R | 2 |
| Fahrleitner-Pammer, A | 4 |
| Stepan, JJ | 3 |
| Evangelatos, G | 1 |
| Fragoulis, GE | 1 |
| Anastasilakis, AD | 4 |
| Iliopoulos, A | 1 |
| Martino, G | 1 |
| Bellone, F | 1 |
| Vicario, CM | 1 |
| Gaudio, A | 1 |
| Caputo, A | 1 |
| Corica, F | 1 |
| Squadrito, G | 1 |
| Schwarz, P | 1 |
| Morabito, N | 1 |
| Catalano, A | 1 |
| Albert, SG | 1 |
| Reddy, S | 1 |
| Liel, Y | 2 |
| Plakht, Y | 1 |
| Tailakh, MA | 1 |
| Misof, BM | 2 |
| Blouin, S | 2 |
| Lueger, S | 1 |
| Paschalis, EP | 6 |
| Recker, RR | 7 |
| Phipps, R | 7 |
| Klaushofer, K | 6 |
| Roschger, P | 5 |
| Karlsson, L | 1 |
| Mesterton, J | 1 |
| Tepie, MF | 1 |
| Intorcia, M | 1 |
| Overbeek, J | 1 |
| Ström, O | 4 |
| Russo, LA | 2 |
| Greenspan, SL | 6 |
| Zikan, V | 2 |
| Bagur, A | 2 |
| Malouf-Sierra, J | 1 |
| Lakatos, P | 2 |
| Horne, AM | 1 |
| Mihov, B | 1 |
| Reid, IR | 1 |
| Naylor, KE | 2 |
| Bradburn, M | 1 |
| Paggiosi, MA | 2 |
| Gossiel, F | 2 |
| Peel, NFA | 1 |
| McCloskey, EV | 3 |
| Walsh, JS | 3 |
| Eastell, R | 13 |
| Lee, DR | 1 |
| Lee, J | 1 |
| Doms, S | 1 |
| Verlinden, L | 1 |
| Vanhevel, J | 1 |
| Janssens, I | 1 |
| Bouillon, R | 1 |
| De Clercq, P | 1 |
| Verstuyf, A | 1 |
| Moericke, R | 1 |
| Hiligsmann, M | 2 |
| Reginster, JY | 10 |
| Von Schacht, E | 1 |
| Dambacher, MA | 1 |
| Ringe, JD | 8 |
| Dukas, L | 1 |
| Lindsay, R | 10 |
| Watts, NB | 15 |
| Lange, JL | 4 |
| Delmas, PD | 14 |
| Silverman, SL | 5 |
| Chung, HY | 3 |
| Koo, J | 1 |
| Kwon, SK | 1 |
| Kang, MI | 3 |
| Moon, SH | 2 |
| Park, JY | 1 |
| Shin, CS | 2 |
| Yoon, BK | 2 |
| Yoon, HK | 3 |
| Chang, JS | 1 |
| Chung, YS | 3 |
| Park, HM | 2 |
| Anitha, D | 1 |
| Kim, KJ | 1 |
| Lim, SK | 2 |
| Lee, T | 1 |
| Kasukawa, Y | 2 |
| Miyakoshi, N | 2 |
| Ebina, T | 1 |
| Aizawa, T | 1 |
| Hongo, M | 2 |
| Nozaka, K | 1 |
| Ishikawa, Y | 2 |
| Saito, H | 1 |
| Chida, S | 1 |
| Shimada, Y | 2 |
| Parthan, A | 1 |
| Kruse, M | 1 |
| Yurgin, N | 1 |
| Huang, J | 1 |
| Viswanathan, HN | 1 |
| Taylor, D | 1 |
| Roux, C | 13 |
| Hofbauer, LC | 1 |
| Ho, PR | 3 |
| Wark, JD | 3 |
| Zillikens, MC | 1 |
| Hawkins, F | 1 |
| Micaelo, M | 1 |
| Papaioannou, N | 1 |
| Stone, M | 1 |
| Ferreira, I | 3 |
| Siddhanti, S | 1 |
| Wagman, RB | 2 |
| Cairoli, E | 1 |
| Eller-Vainicher, C | 1 |
| Ulivieri, FM | 1 |
| Zhukouskaya, VV | 1 |
| Palmieri, S | 1 |
| Morelli, V | 1 |
| Beck-Peccoz, P | 1 |
| Chiodini, I | 1 |
| Gopal, GK | 1 |
| Tam, KL | 1 |
| Krishnan, SP | 1 |
| Maddern, IL | 1 |
| Svanström, H | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Bolognese, MA | 3 |
| Hall, J | 1 |
| Bone, HG | 1 |
| Bonnick, S | 3 |
| van den Bergh, JP | 2 |
| Dakin, P | 1 |
| Recknor, C | 1 |
| Messori, A | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Marinai, C | 1 |
| Peel, N | 1 |
| McCloskey, E | 1 |
| Ste-Marie, LG | 5 |
| Chavassieux, P | 1 |
| Lundy, MW | 1 |
| Fernández Ayora, A | 1 |
| Herion, F | 1 |
| Rompen, E | 1 |
| Magremanne, M | 1 |
| Lambert, F | 1 |
| Hagino, H | 2 |
| Yoshida, S | 1 |
| Hashimoto, J | 2 |
| Matsunaga, M | 1 |
| Tobinai, M | 1 |
| Nakamura, T | 1 |
| Agodoa, I | 1 |
| Mukaiyama, K | 1 |
| Kamimura, M | 1 |
| Uchiyama, S | 1 |
| Ikegami, S | 1 |
| Nakamura, Y | 1 |
| Kato, H | 1 |
| Dueck, AC | 1 |
| Singh, J | 1 |
| Atherton, P | 1 |
| Liu, H | 1 |
| Novotny, P | 1 |
| Hines, S | 1 |
| Loprinzi, CL | 1 |
| Perez, EA | 1 |
| Tan, A | 1 |
| Burger, K | 1 |
| Zhao, X | 2 |
| Diekmann, B | 1 |
| Sloan, JA | 1 |
| Vujevich, KT | 3 |
| Brufsky, A | 3 |
| Lembersky, BC | 2 |
| van Londen, GJ | 2 |
| Jankowitz, RC | 1 |
| Puhalla, SL | 1 |
| Rastogi, P | 1 |
| Perera, S | 3 |
| Oral, A | 1 |
| Lorenc, R | 1 |
| Jacques, RM | 1 |
| Paggiosi, M | 1 |
| Peel, NF | 1 |
| Gu, JM | 1 |
| Wang, L | 1 |
| Lin, H | 1 |
| Chen, DC | 1 |
| Tang, H | 1 |
| Jin, XL | 1 |
| Xia, WB | 1 |
| Hu, YQ | 1 |
| Fu, WZ | 1 |
| He, JW | 1 |
| Zhang, H | 1 |
| Wang, C | 1 |
| Yue, H | 1 |
| Hu, WW | 1 |
| Liu, YJ | 1 |
| Zhang, ZL | 1 |
| Feldbrin, Z | 1 |
| Luckish, A | 1 |
| Shargorodsky, M | 1 |
| Vinicola, V | 1 |
| Giampà, E | 1 |
| Di Bonito, M | 1 |
| Ferretti, V | 1 |
| Nuvoli, G | 1 |
| Paoletti, F | 1 |
| Piazzini, M | 1 |
| Ranieri, M | 1 |
| Tuveri, MA | 1 |
| Pawlowski, JW | 1 |
| Martin, BR | 2 |
| McCabe, GP | 2 |
| McCabe, L | 1 |
| Jackson, GS | 2 |
| Peacock, M | 2 |
| Barnes, S | 2 |
| Weaver, CM | 2 |
| Gatti, D | 1 |
| Adami, S | 6 |
| Viapiana, O | 1 |
| Rossini, M | 2 |
| Eiken, P | 1 |
| Vestergaard, P | 3 |
| Ebina, K | 1 |
| Noguchi, T | 1 |
| Hirao, M | 1 |
| Kaneshiro, S | 1 |
| Yukioka, M | 1 |
| Yoshikawa, H | 1 |
| Xu, LH | 1 |
| Adams-Huet, B | 1 |
| Poindexter, JR | 1 |
| Maalouf, NM | 1 |
| Reiss, S | 1 |
| Sultan, D | 1 |
| Marques, A | 1 |
| Lourenço, Ó | 1 |
| Ortsäter, G | 1 |
| Borgström, F | 5 |
| Kanis, JA | 8 |
| da Silva, JA | 1 |
| Bhavsar, NV | 1 |
| Trivedi, SR | 1 |
| Dulani, K | 1 |
| Brahmbhatt, N | 1 |
| Shah, S | 1 |
| Chaudhri, D | 1 |
| Uğurlar, M | 1 |
| Waltman, NL | 2 |
| Cullen, DM | 1 |
| Berg, K | 2 |
| Langel, M | 1 |
| Meisinger, M | 1 |
| Portelli-Trinidad, A | 1 |
| Lang, M | 1 |
| Durden, E | 1 |
| Pinto, L | 1 |
| Lopez-Gonzalez, L | 1 |
| Juneau, P | 1 |
| Barron, R | 1 |
| Imai, T | 1 |
| Tanaka, S | 1 |
| Kawakami, K | 1 |
| Miyazaki, T | 1 |
| Shiraki, M | 3 |
| Giannini, S | 1 |
| Bianchi, G | 1 |
| Sinigaglia, L | 2 |
| Di Munno, O | 2 |
| Fiore, CE | 1 |
| Kumm, J | 1 |
| Ivaska, KK | 1 |
| Rohtla, K | 1 |
| Vaananen, K | 1 |
| Tamm, A | 1 |
| Iizuka, T | 1 |
| Matsukawa, M | 1 |
| Miller, PD | 6 |
| Luckey, M | 1 |
| Adachi, J | 4 |
| Saag, K | 2 |
| Seeman, E | 3 |
| Boonen, S | 9 |
| Meeves, S | 1 |
| Lang, TF | 1 |
| Bilezikian, JP | 2 |
| Moro-Alvarez, MJ | 1 |
| Díaz-Curiel, M | 3 |
| Cuzick, J | 1 |
| Tosteson, AN | 1 |
| Burge, RT | 2 |
| Marshall, DA | 1 |
| Bonnick, SL | 2 |
| Beck, TJ | 1 |
| Cosman, F | 1 |
| Hochberg, MC | 3 |
| Wang, H | 1 |
| de Papp, AE | 4 |
| Hatakeyama, N | 1 |
| Ozasa, Y | 1 |
| Wada, T | 1 |
| Verhaar, HJ | 1 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Adachi, JD | 9 |
| Kennedy, CC | 1 |
| Papaioannou, A | 6 |
| Ioannidis, G | 2 |
| Leslie, WD | 1 |
| Walker, V | 1 |
| Vrijens, B | 2 |
| Taylor, EB | 1 |
| Dundar, U | 1 |
| Kavuncu, V | 1 |
| Ciftci, IH | 1 |
| Evcik, D | 1 |
| Solak, O | 1 |
| Cakir, T | 1 |
| Beary, JF | 3 |
| Matzkin, E | 5 |
| Darbie, LM | 1 |
| Burgio, DE | 7 |
| Racewicz, AJ | 2 |
| Fardellone, P | 2 |
| Kruse, HP | 5 |
| Amling, M | 1 |
| van der Geest, SA | 1 |
| Möller, G | 2 |
| Binkley, N | 1 |
| Martens, MG | 1 |
| Derman, RJ | 1 |
| Greenwald, M | 1 |
| Kohles, JD | 1 |
| Bachmann, GA | 1 |
| Wasserfallen, JB | 1 |
| Krieg, MA | 1 |
| Greiner, RA | 1 |
| Lamy, O | 1 |
| Frampton, JE | 1 |
| Rackoff, P | 1 |
| Shiraishi, A | 1 |
| Miyabe, S | 1 |
| Nakano, T | 1 |
| Umakoshi, Y | 1 |
| Ito, M | 1 |
| Mihara, M | 1 |
| Coelho, J | 1 |
| Johansson, H | 1 |
| Oden, A | 1 |
| Borah, B | 5 |
| Dufresne, T | 1 |
| Nurre, J | 1 |
| Chmielewski, P | 1 |
| Wagner, L | 1 |
| Lundy, M | 1 |
| Bouxsein, M | 1 |
| Zebaze, R | 1 |
| Nolan, JR | 1 |
| McCabe, LD | 1 |
| Reinwald, S | 1 |
| Boris, ME | 1 |
| Winkler-Budenhofer, UC | 1 |
| Ihrler, S | 1 |
| Göke, B | 1 |
| Kolligs, FT | 1 |
| Bruyère, O | 1 |
| Abelson, A | 2 |
| Gold, DT | 4 |
| Thomas, T | 4 |
| Twiss, JJ | 1 |
| Ott, CD | 1 |
| Gross, GJ | 1 |
| Lindsey, AM | 1 |
| Moore, TE | 1 |
| Kupzyk, K | 1 |
| Lee, IK | 1 |
| Park, IH | 1 |
| Kim, GS | 2 |
| Min, YK | 1 |
| Chung, DJ | 1 |
| Kim, YK | 1 |
| Choi, WH | 1 |
| Shong, MH | 1 |
| Park, JH | 1 |
| Byun, DW | 1 |
| Lee, YS | 1 |
| Kwon, NH | 1 |
| Sereika, SM | 3 |
| Bhattacharya, R | 2 |
| Allen, MR | 1 |
| Erickson, AM | 1 |
| Wang, X | 1 |
| Burr, DB | 1 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Masud, T | 1 |
| McClung, M | 6 |
| Ohtori, S | 3 |
| Akazawa, T | 1 |
| Murata, Y | 1 |
| Kinoshita, T | 1 |
| Yamashita, M | 1 |
| Nakagawa, K | 1 |
| Inoue, G | 3 |
| Nakamura, J | 3 |
| Orita, S | 3 |
| Ochiai, N | 3 |
| Kishida, S | 3 |
| Takaso, M | 3 |
| Eguchi, Y | 3 |
| Yamauchi, K | 3 |
| Suzuki, M | 3 |
| Aoki, Y | 3 |
| Takahashi, K | 3 |
| Yamaguchi, K | 1 |
| Oizumi, T | 1 |
| Funayama, H | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Van Poznak, C | 1 |
| Hannon, RA | 2 |
| Mackey, JR | 1 |
| Campone, M | 1 |
| Apffelstaedt, JP | 1 |
| Clack, G | 1 |
| Barlow, D | 1 |
| Makris, A | 1 |
| Stovall, DW | 1 |
| Beard, MK | 1 |
| Barbier, S | 1 |
| Chen, E | 3 |
| Rosenberg, E | 1 |
| Bahlous, A | 1 |
| Bouzid, K | 1 |
| Sahli, H | 1 |
| Sallami, S | 1 |
| Abdelmoula, J | 1 |
| Klemes, AB | 1 |
| Zhou, X | 4 |
| Markopoulos, C | 2 |
| Tzoracoleftherakis, E | 2 |
| Polychronis, A | 1 |
| Venizelos, B | 2 |
| Dafni, U | 1 |
| Xepapadakis, G | 2 |
| Papadiamantis, J | 1 |
| Zobolas, V | 2 |
| Misitzis, J | 2 |
| Kalogerakos, K | 1 |
| Sarantopoulou, A | 1 |
| Siasos, N | 1 |
| Koukouras, D | 2 |
| Antonopoulou, Z | 1 |
| Lazarou, S | 1 |
| Gogas, H | 2 |
| Kanazawa, I | 1 |
| Yamaguchi, T | 1 |
| Hayashi, K | 1 |
| Takase, H | 1 |
| Shimizu, T | 1 |
| Sugimoto, T | 1 |
| Yemisci, OU | 1 |
| Yalbuzdag, SA | 1 |
| Karatas, M | 1 |
| Lee, S | 1 |
| Glendenning, P | 1 |
| Inderjeeth, CA | 1 |
| Duque, G | 1 |
| Li, W | 1 |
| Adams, M | 1 |
| Xu, S | 1 |
| Fratzl-Zelman, N | 2 |
| Qiu, S | 1 |
| Phipps, RJ | 3 |
| Palnitkar, S | 1 |
| Sudhaker Rao, D | 1 |
| Jönsson, B | 4 |
| Siris, ES | 1 |
| Tosteson, A | 1 |
| Okamoto, K | 1 |
| Inaba, M | 1 |
| Furumitsu, Y | 1 |
| Ban, A | 1 |
| Mori, N | 1 |
| Yukioka, K | 1 |
| Imanishi, Y | 1 |
| Nishizawa, Y | 1 |
| Katahira, G | 1 |
| Yoshizaki, T | 1 |
| Winzenberg, T | 1 |
| Jones, G | 1 |
| Zinnuroglu, M | 1 |
| Dincel, AS | 1 |
| Kosova, F | 1 |
| Sepici, V | 1 |
| Karatas, GK | 1 |
| Polyzos, SA | 3 |
| Bratengeier, C | 1 |
| Woloszczuk, W | 1 |
| Papatheodorou, A | 1 |
| Terpos, E | 1 |
| Goldstein, JL | 1 |
| Klemes, A | 1 |
| Osaki, M | 1 |
| Tatsuki, K | 1 |
| Hashikawa, T | 1 |
| Norimatsu, T | 1 |
| Chiba, K | 1 |
| Motokawa, S | 1 |
| Furuichi, I | 1 |
| Doiguchi, Y | 1 |
| Aoyagi, K | 1 |
| Shindo, H | 1 |
| Cheen, MH | 1 |
| Kong, MC | 1 |
| Zhang, RF | 1 |
| Tee, FM | 1 |
| Chandran, M | 1 |
| Chin, SO | 1 |
| Koh, JM | 2 |
| Karadag-Saygi, E | 1 |
| Akyuz, G | 1 |
| Bizargity, P | 1 |
| Ay, P | 1 |
| Fitzpatrick, SG | 1 |
| Stavropoulos, MF | 1 |
| Bowers, LM | 1 |
| Neuman, AN | 1 |
| Hinkson, DW | 1 |
| Green, JG | 1 |
| Bhattacharyya, I | 1 |
| Cohen, DM | 1 |
| Gamsjaeger, S | 1 |
| Buchinger, B | 1 |
| Zoehrer, R | 3 |
| Lai, PS | 2 |
| Chua, SS | 2 |
| Chew, YY | 1 |
| Chan, SP | 2 |
| Zanchetta, J | 2 |
| Benhamou, CL | 5 |
| Balske, A | 3 |
| Sarley, J | 1 |
| McCullough, LK | 1 |
| Reid, DM | 3 |
| Devogelaer, JP | 1 |
| Lau, CS | 1 |
| Papanastasiou, P | 1 |
| Bucci-Rechtweg, C | 1 |
| Su, G | 1 |
| Sambrook, PN | 1 |
| Frost, ML | 1 |
| Siddique, M | 1 |
| Blake, GM | 1 |
| Moore, AE | 1 |
| Marsden, PK | 1 |
| Schleyer, PJ | 1 |
| Fogelman, I | 4 |
| Hadji, P | 1 |
| Zanchetta, JR | 4 |
| Russo, L | 1 |
| Recknor, CP | 1 |
| Saag, KG | 2 |
| McKiernan, FE | 1 |
| Alam, J | 1 |
| Krege, JH | 1 |
| Lakshmanan, MC | 1 |
| Masica, DN | 1 |
| Mitlak, BH | 1 |
| Stock, JL | 1 |
| Sergi, G | 1 |
| Pintore, G | 1 |
| Falci, C | 1 |
| Veronese, N | 1 |
| Berton, L | 1 |
| Perissinotto, E | 1 |
| Basso, U | 1 |
| Brunello, A | 1 |
| Monfardini, S | 1 |
| Manzato, E | 1 |
| Coin, A | 1 |
| Cooper, C | 2 |
| Lorenc, RS | 1 |
| Rizzoli, R | 5 |
| Bae, SJ | 1 |
| Kim, BJ | 1 |
| Lim, KH | 1 |
| Lee, SH | 1 |
| Kim, HK | 1 |
| Horlait, S | 2 |
| Atlan, P | 1 |
| Racewicz, A | 2 |
| Man, Z | 4 |
| Eusebio, RA | 2 |
| Delmas, P | 2 |
| Takakuwa, M | 1 |
| Iwamoto, J | 3 |
| Kuniyoshi, K | 2 |
| Ishikawa, T | 2 |
| Miyagi, M | 2 |
| Kamoda, H | 2 |
| Kubota, G | 2 |
| Sakuma, Y | 2 |
| Oikawa, Y | 2 |
| Inage, K | 2 |
| Sainoh, T | 2 |
| Ozawa, T | 1 |
| Toyone, T | 2 |
| Chau, D | 1 |
| Becker, DL | 1 |
| Coombes, ME | 1 |
| Wenderoth, D | 2 |
| Yates, J | 1 |
| Tlustochowicz, W | 2 |
| Eusebio, R | 2 |
| Balske, AM | 1 |
| Olszynski, WP | 5 |
| Recker, R | 2 |
| Wang, G | 1 |
| Zhu, Z | 1 |
| Lei, C | 1 |
| Li, M | 2 |
| Liu, F | 1 |
| Mao, Y | 1 |
| Yu, Z | 1 |
| Liu, M | 1 |
| Tang, T | 1 |
| Peris, P | 1 |
| Atkinson, EJ | 1 |
| Gössl, M | 1 |
| Kane, TL | 1 |
| McCready, LK | 1 |
| Lerman, A | 1 |
| Khosla, S | 2 |
| McGregor, UI | 1 |
| Steinbuch, M | 1 |
| D'Agostino, RB | 1 |
| Mandel, JS | 1 |
| Gabrielson, E | 1 |
| Stemhagen, A | 1 |
| Hofman, A | 1 |
| Cranney, A | 3 |
| Weaver, B | 2 |
| Zytaruk, N | 2 |
| Robinson, V | 3 |
| Shea, B | 3 |
| Wells, G | 3 |
| Guyatt, G | 2 |
| Kherani, RB | 1 |
| Thomson, AB | 2 |
| Marshall, JK | 1 |
| Hunt, RH | 2 |
| Provenza, JM | 2 |
| Lanza, FL | 3 |
| Royer, MG | 1 |
| Li, Z | 8 |
| Blank, MA | 3 |
| Diez-Perez, A | 1 |
| Tremaine, WJ | 1 |
| Srivastava, M | 1 |
| Deal, C | 1 |
| Baranauskaite, A | 1 |
| Savickiene, A | 1 |
| Eriksen, EF | 4 |
| Melsen, F | 1 |
| Sod, E | 3 |
| Barton, I | 4 |
| Chines, A | 5 |
| Minne, HW | 2 |
| Pollähne, W | 1 |
| Pfeifer, M | 1 |
| Begerow, B | 1 |
| Hinz, C | 1 |
| Deal, CL | 1 |
| Zethraeus, N | 1 |
| Josse, RG | 1 |
| Hamdy, RC | 3 |
| Hughes, RA | 1 |
| Manhart, MD | 4 |
| Calligeros, D | 1 |
| Felsenberg, D | 5 |
| Bartl, R | 1 |
| Delaney, MF | 2 |
| Hurwitz, S | 1 |
| Shaw, J | 1 |
| LeBoff, MS | 1 |
| Hamilton, B | 1 |
| McCoy, K | 1 |
| Taggart, H | 1 |
| Fukunaga, M | 2 |
| Kushida, K | 2 |
| Kishimoto, H | 2 |
| Taketani, Y | 1 |
| Minaguchi, H | 1 |
| Inoue, T | 2 |
| Morita, R | 1 |
| Morii, H | 2 |
| Yamamoto, K | 2 |
| Ohashi, Y | 2 |
| Orimo, H | 2 |
| Kasibhatla, C | 2 |
| Brown, J | 2 |
| Derman, R | 1 |
| Garnero, P | 1 |
| Dufresne, TE | 4 |
| Chmielewski, PA | 3 |
| Johnson, TD | 3 |
| Hosking, D | 3 |
| Andia, JC | 1 |
| Välimäki, M | 1 |
| Benhamou, L | 1 |
| Yacik, C | 1 |
| Rybak-Feglin, A | 1 |
| Petruschke, RA | 2 |
| Zaru, L | 1 |
| Santora, AC | 1 |
| Ettinger, MP | 2 |
| Waldegger, L | 1 |
| Harrington, JT | 1 |
| Brandi, ML | 4 |
| Civitelli, R | 2 |
| Grauer, A | 3 |
| Kessenich, C | 1 |
| Wei, GS | 1 |
| Jackson, JL | 1 |
| Hatzigeorgiou, C | 1 |
| Tofferi, JK | 1 |
| Curković, B | 1 |
| Jackson, RD | 1 |
| Songcharoen, S | 1 |
| Valent, D | 1 |
| Harris, ST | 3 |
| Chines, AA | 3 |
| Hanley, DA | 2 |
| Johnell, O | 3 |
| Brecht, JG | 2 |
| Möhrke, W | 2 |
| Oestreich, A | 2 |
| Huppertz, E | 2 |
| Itabashi, A | 2 |
| Kaneda, K | 1 |
| Nawata, H | 1 |
| Barton, IP | 6 |
| van Staa, TP | 1 |
| Marx, J | 1 |
| Mellström, DD | 1 |
| Sörensen, OH | 2 |
| Goemaere, S | 1 |
| Johnson, T | 1 |
| El-Hajj Fuleihan, G | 1 |
| Zizic, TM | 2 |
| Emkey, R | 3 |
| Keller, MI | 1 |
| Sarioglu, M | 1 |
| Tuzun, C | 1 |
| Unlu, Z | 1 |
| Tikiz, C | 1 |
| Taneli, F | 1 |
| Uyanik, BS | 1 |
| Rosen, CJ | 1 |
| Miller, P | 1 |
| Broy, S | 1 |
| Kagan, R | 2 |
| Thompson, DE | 2 |
| Leung, JY | 1 |
| Ho, AY | 1 |
| Ip, TP | 1 |
| Lee, G | 1 |
| Kung, AW | 2 |
| Chapurlat, RD | 3 |
| Barger-Lux, J | 1 |
| Christensen, PM | 1 |
| Sørensen, HA | 1 |
| Tanriverdi, HA | 1 |
| Barut, A | 1 |
| Sarikaya, S | 1 |
| Ritman, EL | 2 |
| Jorgensen, SM | 2 |
| Liu, S | 2 |
| Sacha, J | 1 |
| Turner, RT | 2 |
| Høiseth, A | 1 |
| Palomba, S | 1 |
| Orio, F | 1 |
| Manguso, F | 1 |
| Falbo, A | 1 |
| Russo, T | 1 |
| Tolino, A | 1 |
| Tauchmanovà, L | 1 |
| Colao, A | 1 |
| Doldo, P | 1 |
| Mastrantonio, P | 1 |
| Zullo, F | 1 |
| Stevenson, M | 1 |
| Jones, ML | 1 |
| De Nigris, E | 1 |
| Brewer, N | 1 |
| Davis, S | 1 |
| Oakley, J | 1 |
| Meredith, MP | 2 |
| Chesnut, CH | 4 |
| White, NJ | 1 |
| Perry, CM | 1 |
| Pande, I | 1 |
| Hosking, DJ | 1 |
| Rackoff, PJ | 1 |
| Sebba, A | 2 |
| Barrera, BA | 1 |
| Wilton, L | 1 |
| Harris, S | 1 |
| Shakir, SA | 1 |
| Heaney, RP | 3 |
| Valent, DJ | 1 |
| Cramer, JA | 1 |
| Amonkar, MM | 1 |
| Hebborn, A | 1 |
| Altman, R | 1 |
| Poole, KE | 1 |
| Warburton, EA | 1 |
| Reeve, J | 1 |
| Dunlap, LE | 1 |
| Gass, ML | 1 |
| Holick, MF | 1 |
| Leib, ES | 1 |
| Lewiecki, ME | 1 |
| Maricic, M | 1 |
| Christoffersen, H | 1 |
| Holmegaard, SN | 1 |
| Hooper, MJ | 1 |
| Ebeling, PR | 1 |
| Roberts, AP | 1 |
| Graham, JJ | 1 |
| Nicholson, GC | 1 |
| D'Emden, M | 1 |
| Ernst, TF | 1 |
| Li, Y | 1 |
| Zhang, Z | 1 |
| Deng, X | 1 |
| Chen, L | 1 |
| Reach, G | 1 |
| Epstein, S | 1 |
| Wilson, KM | 1 |
| Hiltbrunner, V | 1 |
| Schimmer, RC | 1 |
| Lee, E | 1 |
| Wutoh, AK | 1 |
| Xue, Z | 1 |
| Hillman, JJ | 1 |
| Zuckerman, IH | 1 |
| Gass, M | 1 |
| Dawson-Hughes, B | 1 |
| Carlsson, A | 1 |
| Sintonen, H | 1 |
| Haentjens, P | 1 |
| Burge, R | 1 |
| Sibonga, JD | 1 |
| Kiel, DP | 1 |
| Hochberg, M | 1 |
| Burnett, SM | 1 |
| Penning-van Beest, FJ | 2 |
| Goettsch, WG | 1 |
| Erkens, JA | 2 |
| Herings, RM | 2 |
| Ilter, E | 1 |
| Karalok, H | 1 |
| Tufekci, EC | 1 |
| Batur, O | 1 |
| Takeda, T | 2 |
| Sato, Y | 2 |
| Hofstaetter, JG | 1 |
| Durchschlag, E | 2 |
| Fratzl, P | 3 |
| Blackhouse, G | 1 |
| Mosekilde, L | 2 |
| Langdahl, B | 1 |
| Bhattacharya, RK | 1 |
| Vogel, VG | 2 |
| Bornstein, MM | 1 |
| Oberli, K | 1 |
| Stauffer, E | 1 |
| Buser, D | 1 |
| Kendler, D | 2 |
| Weryha, G | 2 |
| Marques-Neto, JF | 2 |
| Gaines, KA | 1 |
| Verbruggen, N | 2 |
| Melton, ME | 2 |
| Briot, K | 1 |
| Trémollières, F | 2 |
| Ozgocmen, S | 1 |
| Kaya, H | 1 |
| Fadillioglu, E | 1 |
| Yilmaz, Z | 1 |
| Pols, HA | 1 |
| Cahall, D | 1 |
| Keen, R | 1 |
| Jodar, E | 1 |
| Iolascon, G | 1 |
| Varbanov, A | 1 |
| Mann, B | 1 |
| Safi, W | 1 |
| Trinh, H | 1 |
| Lambrinoudaki, I | 1 |
| Christodoulakos, G | 1 |
| Botsis, D | 1 |
| Pasion, EG | 1 |
| Sivananthan, SK | 1 |
| Chen, SH | 1 |
| Chen, YJ | 1 |
| Mirasol, R | 1 |
| Tay, BK | 1 |
| Shah, GA | 1 |
| Khan, MA | 1 |
| Tam, F | 1 |
| Hall, BJ | 1 |
| Thiebaud, D | 1 |
| Imoto, K | 1 |
| Phillips, MB | 1 |
| Brookhart, MA | 2 |
| Avorn, J | 1 |
| Katz, JN | 2 |
| Finkelstein, JS | 1 |
| Arnold, M | 1 |
| Polinski, JM | 1 |
| Patrick, AR | 1 |
| Mogun, H | 1 |
| Solmon, DH | 1 |
| Altintaş, F | 1 |
| Ozkut, AT | 1 |
| Beyzadeoğlu, T | 1 |
| Eren, A | 1 |
| Güven, M | 1 |
| Yanik, B | 1 |
| Bavbek, N | 1 |
| Yanik, T | 1 |
| Inegöl, I | 1 |
| Kanbay, M | 1 |
| Turgut, FH | 1 |
| Uz, E | 1 |
| Akçay, A | 1 |
| Bunyaratavej, N | 1 |
| Denk, E | 1 |
| Hillegonds, D | 1 |
| Hurrell, RF | 1 |
| Vogel, J | 1 |
| Fattinger, K | 1 |
| Häuselmann, HJ | 1 |
| Kraenzlin, M | 1 |
| Walczyk, T | 1 |
| Giljević, Z | 1 |
| Vlak, T | 1 |
| Moro Alvarez, MJ | 1 |
| Karam, R | 1 |
| Camm, J | 1 |
| Strampel, W | 1 |
| Mamdani, M | 1 |
| Kopp, A | 1 |
| Hawker, G | 1 |
| McKeever, CD | 2 |
| D'Amelio, P | 1 |
| Grimaldi, A | 1 |
| Di Bella, S | 1 |
| Tamone, C | 1 |
| Brianza, SZ | 1 |
| Ravazzoli, MG | 1 |
| Bernabei, P | 1 |
| Cristofaro, MA | 1 |
| Pescarmona, GP | 1 |
| Isaia, G | 3 |
| Schofield, PJ | 1 |
| Cahall, DL | 1 |
| Cline, GA | 1 |
| Grima, DT | 1 |
| Thompson, MF | 1 |
| Pasquale, MK | 1 |
| Välimäki, MJ | 1 |
| Farrerons-Minguella, J | 1 |
| Halse, J | 1 |
| Kröger, H | 1 |
| Maroni, M | 1 |
| Mulder, H | 1 |
| Muñoz-Torres, M | 1 |
| Sääf, M | 1 |
| Snorre Øfjord, E | 1 |
| Cesareo, R | 1 |
| Iozzino, M | 1 |
| Alva, D | 1 |
| Napolitano, C | 1 |
| De Rosa, B | 1 |
| Contini, S | 1 |
| Mallardo, L | 1 |
| Lauria, A | 1 |
| Reda, G | 1 |
| Orsini, A | 1 |
| Tanaka, I | 1 |
| Oshima, H | 1 |
| Abe, Y | 1 |
| Ishikawa, H | 1 |
| Fukao, A | 1 |
| Boucher, M | 1 |
| Coyle, D | 1 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Goulis, DG | 2 |
| Gerou, S | 2 |
| Koukoulis, G | 1 |
| Kita, M | 2 |
| Avramidis, A | 2 |
| Luisetto, G | 1 |
| Silvestri, S | 1 |
| Agnusdei, D | 1 |
| Gentilella, R | 1 |
| Nuti, R | 1 |
| Hustad, CM | 1 |
| Mahlis, EM | 1 |
| Anić, B | 1 |
| Olson, M | 1 |
| Dane, C | 1 |
| Dane, B | 1 |
| Cetin, A | 1 |
| Erginbas, M | 1 |
| Koukoulis, GN | 1 |
| Efstathiadou, Z | 1 |
| Gärtner, R | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Solomon, DH | 1 |
| Jee, WS | 2 |
| Lin, BY | 1 |
| Ma, YF | 1 |
| Ke, HZ | 2 |
| Søgaard, CH | 1 |
| Thomsen, JS | 1 |
| Wronski, TJ | 3 |
| Boyce, RW | 2 |
| Paddock, CL | 2 |
| Gleason, JR | 1 |
| Sletsema, WK | 1 |
| Ebert, DC | 1 |
| Stevens, ML | 1 |
| Youngs, TA | 1 |
| Gundersen, HJ | 1 |
| Baumann, BD | 1 |
| Ma, Y | 1 |
| Chen, Y | 1 |
| Gasser, J | 1 |
| Li, XJ | 1 |
| Kimmel, DB | 1 |
| Licata, AA | 3 |
| Balena, R | 1 |
| Confravreux, E | 1 |
| Hardouin, C | 1 |
| Hardy, P | 1 |
| Bremond, A | 1 |
| Clemmesen, B | 1 |
| Ravn, P | 1 |
| Zegels, B | 2 |
| Taquet, AN | 1 |
| Christiansen, C | 1 |
| Mortensen, L | 1 |
| Charles, P | 1 |
| Bekker, PJ | 1 |
| Digennaro, J | 1 |
| Johnston, CC | 1 |
| Li, QN | 1 |
| Liang, NC | 1 |
| Huang, LF | 1 |
| Wu, T | 1 |
| Hu, B | 1 |
| Mo, LE | 1 |
| Genant, HK | 1 |
| Hangartner, T | 1 |
| Keller, M | 1 |
| Hoseyni, MS | 2 |
| Axelrod, DW | 1 |
| Reginster, J | 1 |
| Hooper, M | 1 |
| Lund, B | 1 |
| Ethgen, D | 3 |
| Pack, S | 1 |
| Roumagnac, I | 2 |
| Kessenich, CR | 1 |
| Ribot, C | 1 |
| Smith, R | 1 |
| Leder, BZ | 1 |
| Kronenberg, HM | 1 |
| Lems, WF | 1 |
| Dijkmans, BA | 1 |
| Papapoulos, SE | 1 |
| Compston, JE | 1 |
| Rack, MF | 1 |
| Krajewski, SA | 1 |
| Russell, RG | 1 |
| Collette, J | 1 |
| Zippel, H | 1 |
| Bensen, WG | 1 |
| Diamond, T | 1 |
| Meunier, PJ | 1 |
| Crandall, C | 1 |
| Irani, M | 1 |
| Davidson, M | 1 |
| Moffett, AH | 1 |
| Baylink, DJ | 1 |
| Crusan, CE | 1 |
| Dunn, CJ | 1 |
| Goa, KL | 1 |
| McCormack, J | 1 |
| Netelenbos, JC | 1 |
| Umland, EM | 1 |
| Boyce, EG | 1 |
| Peters, ML | 1 |
| Leonard, M | 1 |
| Gomez-Panzani, E | 1 |
| Bannwarth, B | 1 |
| Sickels, JM | 1 |
| Nip, CS | 1 |
| Iglesias, CP | 1 |
| Torgerson, DJ | 1 |
| Bearne, A | 1 |
| Bose, U | 1 |
| Hodsman, AB | 1 |
| Josse, R | 1 |
| Emkey, RD | 1 |
| Alsayed, N | 1 |
| Davie, MW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients[NCT05346419] | 33 participants (Actual) | Interventional | 2021-07-01 | Completed | |||
| Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures[NCT01709110] | Phase 4 | 1,366 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy[NCT00919711] | Phase 3 | 870 participants (Actual) | Interventional | 2009-09-01 | Completed | ||
| Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women[NCT05347082] | 47 participants (Actual) | Interventional | 2021-04-29 | Completed | |||
| Metabolism and Bone Health[NCT00244907] | Phase 1 | 23 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide[NCT00130403] | Phase 4 | 290 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology[NCT02367846] | Phase 4 | 6 participants (Actual) | Interventional | 2015-01-31 | Active, not recruiting | ||
| Berries and Bones: The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover[NCT02630797] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2017-01-12 | Active, not recruiting | ||
| A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484] | 220 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial[NCT01572545] | 91 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, & 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis.[NCT00541658] | Phase 3 | 923 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)[NCT00089791] | Phase 3 | 7,808 participants (Actual) | Interventional | 2004-08-01 | Completed | ||
| The Pharmacokinetics and Pharmacodynamics Study of Intravenous Zoledronic Acid in Chinese Subjects With Low Bone Mass or Osteoporosis: a Randomized Placebo-controlled Trail[NCT04719650] | Phase 4 | 64 participants (Anticipated) | Interventional | 2021-10-31 | Not yet recruiting | ||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday: Data From a Single Outpatient Endocrine Clinic.[NCT01854086] | 150 participants (Anticipated) | Observational [Patient Registry] | 2013-09-30 | Not yet recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double[NCT00092040] | Phase 3 | 936 participants (Actual) | Interventional | 2003-03-18 | Completed | ||
| A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.[NCT00268632] | Phase 3 | 0 participants | Interventional | 1999-08-31 | Completed | ||
| A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans[NCT02565602] | 10 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health[NCT01053481] | Early Phase 1 | 25 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)[NCT00353080] | Phase 3 | 171 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study[NCT02808988] | Phase 4 | 47 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis[NCT00853723] | Phase 2 | 105 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)[NCT00118508] | 87 participants (Actual) | Interventional | 2003-05-31 | Completed | |||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
A major non-vertebral fracture is a fracture at any of the following non-vertebral sites hip, radius, humerus, ribs, pelvis, tibia and femur. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 18 |
| Risedronate | 31 |
Vertebrae were graded as moderate (SQ2), or severe (SQ3) fractures, based on ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 through L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 26 |
| Risedronate | 63 |
(NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 2 |
| Risedronate | 12 |
"The incidence of new vertebral fractures was assessed by quantitative vertebral morphometry measurements (QM) with qualitative visual semiquantitative grading (SQ) confirmation.~A new vertebral fracture was diagnosed in a vertebra that was non-fractured at the baseline radiological examination. It was defined as a loss of vertebral body height of at least 20% and 4 mm from the baseline radiograph by vertebral QM, based upon placement of six points by a trained, central reader. Any fractures identified by QM were confirmed using SQ: if the vertebral body also had an increase of one or more severity grade, it was considered an incident vertebral fracture." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 28 |
| Risedronate | 64 |
A non-vertebral fracture is a fracture at any of the following non-vertebral sites: clavicle, scapula, ribs, sternum, sacrum, coccyx, humerus, radius, ulna, carpus, pelvis, hip, femur, patella, tibia, fibula, ankle, calcaneus, tarsus, and metatarsal. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object were not considered fragility fractures but traumatic fractures. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 25 |
| Risedronate | 38 |
"A clinical vertebral fracture was defined as a new or worsening vertebral fracture, confirmed by radiography, that was associated with signs and symptoms highly suggestive of a vertebral fracture.~All non-vertebral fractures that occurred and were diagnosed between visits required the confirmation by the site investigators after evaluating the original x-ray film(s), the radiology or surgical report. For clinical vertebral fractures, the final confirmation of the diagnosis required the centralized evaluation by a trained, independent reader." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 30 |
| Risedronate | 61 |
Traumatic fractures were considered if resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 40 |
| Risedronate | 57 |
Worsening of a pre-existing fracture was considered if the decrease in vertebral height was at least one severity grade in the semi-quantitative assessment, confirmed by a trained central reader, where vertebrae were graded as normal (SQ0) or as with mild (SQ1), moderate (SQ2), or severe (SQ3) fractures, defined as ~20 to 25% (mild), ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 to L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 31 |
| Risedronate | 69 |
Participants rated the worst back pain during the 24 hours preceding the visit at baseline and each post-baseline visit. An 11-point numerical back pain rating scale (rated from 0 = no back pain to 10 = worst possible back pain) was used. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 4.5 | 3.4 |
| Teriparatide | 4.5 | 3.4 |
(NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | Centimeter (cm) (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 155.0 | 154.5 |
| Teriparatide | 154.7 | 154.3 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.59 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.62 | 0.68 |
| Teriparatide | 0.59 | 0.65 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United States (US) cross walk algorithm, with scores ranging from -0.11 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.72 | 0.76 |
| Teriparatide | 0.70 | 0.74 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 0.0 |
| Denosumab 60 mg Q6M | 1.4 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 1.1 |
| Denosumab 60 mg Q6M | 3.4 |
Serum Type-1 Collagen C-Telopeptide Percent Change From Baseline at Month 1 (NCT00919711)
Timeframe: Baseline to month 1
| Intervention | Percent Change From Baseline (Median) |
|---|---|
| Risedronate 150 mg QM | -17.0 |
| Denosumab 60 mg Q6M | -77.7 |
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry (NCT00919711)
Timeframe: Baseline to month 12
| Intervention | Percent Change From Baseline (Mean) |
|---|---|
| Risedronate 150 mg QM | 0.5 |
| Denosumab 60 mg Q6M | 2.0 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 5 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 6 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 5 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 4 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 2 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 3 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 2 |
| 35 mg After Breakfast | 2 |
| 35 mg Before Breakfast | 3 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 239 |
| 35 mg After Breakfast | 231 |
| 35 mg Before Breakfast | 233 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 269 |
| 35 mg After Breakfast | 263 |
| 35 mg Before Breakfast | 267 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 255 |
| 35 mg After Breakfast | 255 |
| 35 mg Before Breakfast | 254 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 268 |
| 35 mg After Breakfast | 259 |
| 35 mg Before Breakfast | 268 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.900 |
| 35 mg After Breakfast | 2.148 |
| 35 mg Before Breakfast | 2.164 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.431 |
| 35 mg After Breakfast | 1.986 |
| 35 mg Before Breakfast | 2.047 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.530 |
| 35 mg After Breakfast | 2.108 |
| 35 mg Before Breakfast | 2.328 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.120 |
| 35 mg After Breakfast | 1.385 |
| 35 mg Before Breakfast | 1.246 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.180 |
| 35 mg After Breakfast | 1.507 |
| 35 mg Before Breakfast | 1.717 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.155 |
| 35 mg After Breakfast | 1.482 |
| 35 mg Before Breakfast | 1.717 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.772 |
| 35 mg After Breakfast | 3.691 |
| 35 mg Before Breakfast | 3.828 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 3.056 |
| 35 mg After Breakfast | 4.152 |
| 35 mg Before Breakfast | 4.246 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.186 |
| 35 mg After Breakfast | 2.732 |
| 35 mg Before Breakfast | 2.764 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.297 |
| 35 mg After Breakfast | 2.854 |
| 35 mg Before Breakfast | 2.819 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -32.572 |
| 35 mg After Breakfast | -34.769 |
| 35 mg Before Breakfast | -34.824 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -33.394 |
| 35 mg After Breakfast | -36.143 |
| 35 mg Before Breakfast | -36.810 |
(NCT00541658)
Timeframe: Week 13
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -23.386 |
| 35 mg After Breakfast | -25.141 |
| 35 mg Before Breakfast | -25.191 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -31.273 |
| 35 mg After Breakfast | -33.680 |
| 35 mg Before Breakfast | -32.582 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -31.367 |
| 35 mg After Breakfast | -32.802 |
| 35 mg Before Breakfast | -32.829 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -31.895 |
| 35 mg After Breakfast | -33.450 |
| 35 mg Before Breakfast | -33.507 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -41.451 |
| 35 mg After Breakfast | -49.253 |
| 35 mg Before Breakfast | -48.752 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -44.155 |
| 35 mg After Breakfast | -51.985 |
| 35 mg Before Breakfast | -52.538 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.172 |
| 35 mg After Breakfast | -48.724 |
| 35 mg Before Breakfast | -47.703 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -44.410 |
| 35 mg After Breakfast | -49.185 |
| 35 mg Before Breakfast | -50.048 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.613 |
| 35 mg After Breakfast | 1.748 |
| 35 mg Before Breakfast | 1.685 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.809 |
| 35 mg After Breakfast | 2.130 |
| 35 mg Before Breakfast | 2.099 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 4.147 |
| 35 mg After Breakfast | 5.205 |
| 35 mg Before Breakfast | 5.068 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 4.352 |
| 35 mg After Breakfast | 5.506 |
| 35 mg Before Breakfast | 5.396 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg IRBB | 3.069 |
| 35 mg DRFB + DRBB | 3.334 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.685 |
| 35 mg After Breakfast | 2.816 |
| 35 mg Before Breakfast | 2.529 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 3.035 |
| 35 mg After Breakfast | 3.293 |
| 35 mg Before Breakfast | 3.357 |
(NCT00541658)
Timeframe: 52 weeks / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 3.069 |
| 35 mg After Breakfast | 3.302 |
| 35 mg Before Breakfast | 3.365 |
(NCT00541658)
Timeframe: Week 13
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.331 |
| 35 mg After Breakfast | -46.781 |
| 35 mg Before Breakfast | -46.054 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -44.386 |
| 35 mg After Breakfast | -49.183 |
| 35 mg Before Breakfast | -49.358 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.028 |
| 35 mg After Breakfast | 2.551 |
| 35 mg Before Breakfast | 2.496 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 2.177 |
| 35 mg After Breakfast | 2.821 |
| 35 mg Before Breakfast | 2.764 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | 1.785 |
| 35 mg After Breakfast | 2.073 |
| 35 mg Before Breakfast | 2.075 |
(NCT00541658)
Timeframe: Week 104 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -46.261 |
| 35 mg After Breakfast | -51.079 |
| 35 mg Before Breakfast | -49.454 |
(NCT00541658)
Timeframe: Week 104
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -49.188 |
| 35 mg After Breakfast | -53.927 |
| 35 mg Before Breakfast | -53.186 |
(NCT00541658)
Timeframe: Week 26
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -43.075 |
| 35 mg After Breakfast | -45.705 |
| 35 mg Before Breakfast | -47.692 |
(NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -40.227 |
| 35 mg After Breakfast | -46.599 |
| 35 mg Before Breakfast | -44.630 |
(NCT00541658)
Timeframe: Week 52
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.223 |
| 35 mg After Breakfast | -47.263 |
| 35 mg Before Breakfast | -46.863 |
(NCT00541658)
Timeframe: Week 13
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| 5 mg Before Breakfast | -42.595 |
| 35 mg After Breakfast | -46.366 |
| 35 mg Before Breakfast | -45.420 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 81.8 |
| 35 mg After Breakfast | 87.9 |
| 35 mg Before Breakfast | 90.1 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 82.6 |
| 35 mg After Breakfast | 89.2 |
| 35 mg Before Breakfast | 92.3 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52 / Endpoint
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 81.5 |
| 35 mg After Breakfast | 87.4 |
| 35 mg Before Breakfast | 86.0 |
Responder = a patient showing a positive change (>0 g/cm2) in lumbar spine BMD from baseline to the timepoint. (NCT00541658)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Before Breakfast | 81 |
| 35 mg After Breakfast | 87.5 |
| 35 mg Before Breakfast | 86.4 |
Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 43 |
| Denosumab 60 mg Q6M | 26 |
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms [or both] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture). (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 264 |
| Denosumab 60 mg Q6M | 86 |
Nonvertebral fractures (osteoporotic) were those occurring on study excluding those of the vertebrae (cervical, thoracic, and lumbar), skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges. Fractures associated with high trauma severity (fractures that were the result of a fall from higher than the height of a stool, chair, first rung on a ladder or equivalent (> 20 inches) or was the result of severe trauma other than a fall) and pathologic fractures were excluded from this category. Nonvertebral fractures were required to be confirmed either by radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI), or by documentation in a radiology report, surgical report, or discharge summary. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 293 |
| Denosumab 60 mg Q6M | 238 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.35 |
| PTHrP 600 mcg/Day | -0.34 |
| PTH 20 mcg/Day | -0.82 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.91 |
| PTHrP 600 mcg/Day | 0.54 |
| PTH 20 mcg/Day | 0.61 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.48 |
| PTHrP 600 mcg/Day | -0.99 |
| PTH 20 mcg/Day | -0.97 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 1.89 |
| PTHrP 600 mcg/Day | 1.52 |
| PTH 20 mcg/Day | 2.17 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.68 |
| PTHrP 600 mcg/Day | 0.72 |
| PTH 20 mcg/Day | 0.54 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 42.51 | 65.25 | 67.29 | 58.15 | 53.73 |
| PTHrP 400 mcg/Day | 49.06 | 84.92 | 76.04 | 67.85 | 64.36 |
| PTHrP 600 mcg/Day | 42.49 | 63.07 | 65.15 | 57.02 | 55.08 |
(NCT00853723)
Timeframe: 90 days
| Intervention | mg/gm creatinine (Mean) | |
|---|---|---|
| Baseline | Day 90 | |
| PTH 20 mcg/Day | 209.99 | 232.48 |
| PTHrP 400 mcg/Day | 206.37 | 260.46 |
| PTHrP 600 mcg/Day | 213.07 | 235.25 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.87 | 13.89 | 52.98 | 92.46 |
| PTHrP 400 mcg/Day | -12.40 | 1.60 | 4.13 | 32.65 |
| PTHrP 600 mcg/Day | 10.25 | 9.59 | 14.38 | 25.65 |
(Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine) (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | % excreted (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 2.30 | 2.55 | 2.92 | 2.95 | 3.37 |
| PTHrP 400 mcg/Day | 2.38 | 3.42 | 3.27 | 3.38 | 3.10 |
| PTHrP 600 mcg/Day | 2.71 | 4.18 | 3.74 | 2.89 | 2.89 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 60.67 | 97.27 | 125.46 | 171.49 |
| PTHrP 400 mcg/Day | 32.54 | 48.89 | 34.71 | 46.07 |
| PTHrP 600 mcg/Day | 23.51 | 83.14 | 87.39 | 84.09 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.09 | 4.13 | 4.19 | 4.28 | 4.10 |
| PTHrP 400 mcg/Day | 4.0 | 3.78 | 3.87 | 4.02 | 4.05 |
| PTHrP 600 mcg/Day | 3.93 | 3.68 | 3.71 | 3.97 | 3.98 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90, time 0 | Day 90, time 3 hours | day 90, time 6 hours | |
| PTH 20 mcg/Day | 9.49 | 9.57 | 9.55 | 9.58 | 9.44 | 9.75 | 9.78 |
| PTHrP 400 mcg/Day | 9.48 | 9.95 | 9.73 | 9.71 | 9.56 | 9.90 | 9.90 |
| PTHrP 600 mcg/Day | 9.51 | 9.87 | 9.67 | 9.61 | 9.45 | 9.76 | 9.81 |
"Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP < or = 0.86 then TMP/GFR = TRP x P phos if TRP > 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos~U= urine, P = plasma" (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 3.96 | 4.18 | 4.03 | 4.28 | 4.00 |
| PTHrP 400 mcg/Day | 3.80 | 3.78 | 3.88 | 4.02 | 4.11 |
| PTHrP 600 mcg/Day | 3.71 | 3.47 | 3.61 | 3.84 | 3.90 |
88 reviews available for risedronic acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Netw | 2022 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Aged; Female; Hip Fractures; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractu | 2022 |
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapa | 2022 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Obse | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Huma | 2023 |
History of risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2020 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Dru | 2017 |
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactio | 2012 |
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Densit | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosp | 2014 |
Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
Topics: Aged; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clini | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Iban | 2015 |
Treatment of osteoporosis after alendronate or risedronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Female; Humans; Im | 2016 |
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Drug Administration Sch | 2008 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Sp | 2009 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug-Related Side Effects | 2009 |
Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cli | 2010 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; | 2011 |
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fem | 2012 |
In brief: delayed-release risedronate (Atelvia).
Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Delayed-Action Preparations; Etidronic A | 2011 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; | 2012 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation | 2013 |
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Topics: Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomized Controlled | 2002 |
Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis, | 2002 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Estrogen Replacement Therapy; Etidronic A | 2002 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; | 2002 |
Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Topics: Aged; Alendronate; Calcium Channel Blockers; Canada; Estrogen Replacement Therapy; Etidronic Acid; F | 2003 |
Identifying the osteopenic patient and preventing worsening of the disease.
Topics: Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcitonin; Es | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomi | 2003 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement | 2003 |
Osteoporosis management in the new millennium.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle | 2003 |
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Ac | 2004 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; | 2004 |
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Topics: Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; | 2004 |
Treating osteoporosis in post-menopausal women: a case approach.
Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Mid | 2004 |
Risedronate for prevention and treatment of osteoporosis in postmenopausal women.
Topics: Animals; Bone Density; Bone Remodeling; Chemistry, Pharmaceutical; Clinical Trials as Topic; Etidron | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysi | 2005 |
The use of bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Osteogenesi | 2005 |
Risedronate once a week.
Topics: Bone Density; Calcium Channel Blockers; Drug Administration Schedule; Etidronic Acid; Female; Humans | 2003 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosp | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; | 2004 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; | 2005 |
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Etidronic | 2005 |
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Bo | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Die | 2005 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Est | 2006 |
[Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Congresses as Topic; | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone D | 2006 |
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2006 |
Long-term experience with alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic A | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphon | 2006 |
[Biphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature].
Topics: Administration, Oral; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Etidronic | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Dr | 2007 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandroni | 2006 |
[Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postme | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractu | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph | 2007 |
[HIP study--how to prevent hip fractures?].
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fr | 2007 |
[FACT study].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double- | 2007 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Os | 2008 |
[Risedronate (Actonel)--from randomized clinical trials to real life].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Pos | 2007 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Ca | 2005 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Risedronate: a new bisphosphonate for the treatment of osteoporosis.
Topics: Adrenal Cortex Hormones; Aged; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporos | 2000 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Oste | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Femal | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; | 2000 |
Risedronate: a clinical review.
Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; F | 2001 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 2001 |
Evidence-based medicine: putting theory into practice.
Topics: Alendronate; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based | 2001 |
Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Topics: Bone and Bones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Half-Life; Humans; I | 2001 |
Risedronate: clinical usage.
Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Ostei | 2001 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Ac | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Administration, Oral; Alendronate; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid | 2001 |
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
Topics: Aging; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Mi | 2001 |
Review of risedronate in the treatment of osteoporosis.
Topics: Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Pos | 2001 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
Topics: Aged; Bone Density; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Huma | 2001 |
Risedronate for the prevention of fractures in postmenopausal osteoporosis.
Topics: Aged; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Bone; Humans; MEDLINE; Osteoporos | 2002 |
128 trials available for risedronic acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2022 |
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Osteop | 2020 |
Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcification, Physiologic; Diphosphonates; Fem | 2017 |
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Americas; Bone Density; Bone Density Conservation Agents; Double-Blind Meth | 2018 |
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarker | 2018 |
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Topics: Aged; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Middle Aged; Osteoporos | 2019 |
Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Ch | 2013 |
Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Incidence; Ost | 2014 |
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents | 2014 |
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Dens | 2014 |
Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Calcitonin; Chronic Pain; Drug Ther | 2015 |
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractu | 2014 |
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; | 2015 |
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agen | 2015 |
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Density | 2015 |
Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Cross-Over Stud | 2015 |
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone De | 2016 |
The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data.
Topics: Aged; Asian People; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; China; | 2015 |
Effects of long-term risedronate treatment on serum ferritin levels in postmenopausal women with osteoporosis: the impact of cardiovascular risk factor load.
Topics: Aged; Bone Density Conservation Agents; C-Reactive Protein; Cardiovascular Diseases; Female; Ferriti | 2016 |
Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention in postmenopausal women: a randomized crossover trial.
Topics: Administration, Oral; Aged; Bone and Bones; Calcium; Cross-Over Studies; Dietary Supplements; Dose-R | 2015 |
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Therapy, | 2017 |
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bo | 2008 |
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Anabolic Agents; Bone Density Conservation Agents; | 2008 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents | 2009 |
Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; | 2009 |
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I | 2009 |
Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response R | 2009 |
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; | 2009 |
Risedronate reduces intracortical porosity in women with osteoporosis.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Demography; Etidronic Acid; Fe | 2010 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi | 2009 |
The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone | 2010 |
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cross-Over Studies; Diphosp | 2009 |
The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Double-Blind | 2010 |
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Hu | 2009 |
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Topics: Adult; Age Factors; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation | 2010 |
Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Dose-Resp | 2009 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
Effects of risedronate on bone marrow adipocytes in postmenopausal women.
Topics: Adipocytes; Adipogenesis; Aged; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Et | 2011 |
Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Drug Admini | 2010 |
Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
Topics: Bone Density Conservation Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Administrati | 2010 |
Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study.
Topics: Aged; Ankle Brachial Index; Bone Density; Bone Density Conservation Agents; Carotid Arteries; Etidro | 2010 |
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Epidemiologic Methods; Etid | 2012 |
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalci | 2011 |
The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Et | 2011 |
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Topics: Alendronate; Biomarkers, Pharmacological; Bone and Bones; Bone Density; Bone Density Conservation Ag | 2011 |
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparati | 2012 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone De | 2012 |
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density | 2012 |
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid | 2012 |
Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosp | 2012 |
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind | 2013 |
Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Analgesics; Back Pain; Bone Density; Bone Density Conservation Agents; Calc | 2012 |
Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone | 2012 |
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparati | 2013 |
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Admi | 2013 |
Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Creatinine; | 2013 |
Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Screws; Etidronic Acid | 2013 |
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Topics: Aged; Alendronate; Analysis of Variance; Confidence Intervals; Dose-Response Relationship, Drug; Dru | 2002 |
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Humans; Middle Ag | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etid | 2002 |
Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Incidence; Osteoporosis, Postmenopau | 2003 |
A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calci | 2003 |
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Topics: Aged; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Humans; Middl | 2003 |
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Topics: Aged; Biomarkers; Bone Resorption; Calcium Channel Blockers; Collagen; Collagen Type I; Etidronic Ac | 2003 |
Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Topics: Absorptiometry, Photon; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; | 2003 |
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium C | 2003 |
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Fractures | 2004 |
Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Topics: Aged; Biopsy; Bone and Bones; Etidronic Acid; Female; Humans; Imaging, Three-Dimensional; Osteoporos | 2004 |
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Topics: Aged; Analysis of Variance; Bone Density; Double-Blind Method; Etidronic Acid; Humans; Lumbar Verteb | 2004 |
A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Body Height; Bone and Bones; Collagen; Collagen | 2004 |
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
Topics: Absorptiometry, Photon; Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic | 2004 |
Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; | 2004 |
Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone Density; Canada; Cohort Studies; Collagen; Collagen Type I; Etidron | 2004 |
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Calcium Channel Blockers; Double-Blind Method; Etidronic A | 2004 |
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conserv | 2006 |
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Topics: Aged; Alendronate; Biomarkers; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Double-Bli | 2005 |
The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
Topics: Asian People; Biomarkers; Bone Density; Bone Remodeling; Etidronic Acid; Female; Humans; Middle Aged | 2005 |
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, C | 2005 |
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
Topics: Absorptiometry, Photon; Aged; Anthropometry; Bone Density; Double-Blind Method; Etidronic Acid; Fema | 2005 |
The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Topics: Aged; Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Data Inter | 2005 |
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur; Femur Neck; Humans; I | 2005 |
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
Topics: Bone Density; Double-Blind Method; Etidronic Acid; Humans; Meta-Analysis as Topic; Osteoporosis, Pos | 2005 |
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Topics: Absorptiometry, Photon; Adult; Amino Acids; Biomarkers; Bone Density Conservation Agents; Creatinine | 2005 |
Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Eti | 2005 |
Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
Topics: Adult; Aged; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, | 2006 |
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Femur | 2006 |
Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Metho | 2006 |
Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Topics: Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Etidronic Acid; | 2006 |
Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Topics: Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Calcium; Collage | 2006 |
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Antineoplastic Agents; Bone Density; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Etidron | 2007 |
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Human | 2006 |
Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.
Topics: Adult; Aged; Antioxidants; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitonin; E | 2007 |
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Etidronic Aci | 2007 |
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fem | 2007 |
Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans | 2007 |
[The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collage | 2007 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Fe | 2007 |
Monitoring of Risedronate by biochemical bone markers in clinical practice.
Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bo | 2005 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Eti | 2007 |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Humans; Middl | 2008 |
Fracture risk remains reduced one year after discontinuation of risedronate.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Collag | 2008 |
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
Topics: Aged; Bone Density Conservation Agents; Calcium; Cell Survival; Cells, Cultured; Colony-Forming Unit | 2008 |
Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Collagen Type I; Drug Administration Sche | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodel | 2007 |
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; | 2008 |
Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Meth | 2008 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Collagen Type I; Etidronic Acid; Female | 2008 |
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bo | 2008 |
Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Topics: Aged; Algorithms; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resor | 2008 |
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Topics: Absorptiometry, Photon; Aged; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Fem | 2008 |
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Die | 2008 |
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Topics: Adult; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Do | 1997 |
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; Double-Blind Method | 1997 |
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Topics: Adult; Alkaline Phosphatase; Amino Acids; Bone Density; Calcium Channel Blockers; Creatinine; Double | 1998 |
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Topics: Aged; Analysis of Variance; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Fema | 1999 |
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Algorithms; Australia; Bone Density; Calcium Channe | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; | 2000 |
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Topics: Adult; Alendronate; Duodenoscopy; Duodenum; Endoscopy; Esophagoscopy; Esophagus; Etidronic Acid; Fem | 2000 |
Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women.
Topics: Adult; Aged; Aspirin; Duodenal Ulcer; Endoscopy, Gastrointestinal; Esophagus; Etidronic Acid; Female | 2000 |
Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
Topics: Aged; Calcium Channel Blockers; Collagen; Cross-Linking Reagents; Double-Blind Method; Etidronic Aci | 2001 |
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, | 2001 |
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Topics: Aged; Bone and Bones; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Replace | 2001 |
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal | 2001 |
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Calcium Channel Blockers; Dos | 2002 |
Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Huma | 2002 |
164 other studies available for risedronic acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female | 2022 |
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Canada; Cohort Studies; Female; Hu | 2022 |
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Cost-Benefit Analysis; Female | 2022 |
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Di | 2023 |
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Female; Huma | 2023 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid | 2023 |
Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Asian People; Bone Density; Calcium; Col | 2020 |
Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis.
Topics: Aged; Bone and Bones; Bone Density; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteopor | 2020 |
Efficacy of teriparatide compared with risedronate on FRAX
Topics: Aged; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Osteoporo | 2020 |
Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report.
Topics: Bone Density Conservation Agents; Conservative Treatment; Disease Management; Female; Humans; Middle | 2021 |
Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up.
Topics: Anxiety; Bone Density; Female; Follow-Up Studies; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopa | 2021 |
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD.
Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Cons | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic | 2017 |
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.
Topics: Aged; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clini | 2018 |
Teriparatide vs risedronate for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Teriparatide vs risedronate for osteoporosis - Authors' reply.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, | 2018 |
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Drug Administratio | 2019 |
WY 1048, a 17-methyl 19-nor D-ring analog of vitamin D
Topics: Animals; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Disease Models, Animal; Fe | 2019 |
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-B | 2019 |
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2013 |
Implications of local osteoporosis on the efficacy of anti-resorptive drug treatment: a 3-year follow-up finite element study in risedronate-treated women.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Finite Ele | 2013 |
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation A | 2013 |
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone | 2014 |
Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Femoral | 2014 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Coh | 2014 |
Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis, and dental implant removal.
Topics: Administration, Oral; Aged, 80 and over; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecro | 2015 |
Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 2015 |
Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid | 2015 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarke | 2016 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fema | 2016 |
Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis.
Topics: Abscess; Administration, Oral; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw | 2015 |
Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analys | 2016 |
Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women (12-month study).
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Periodontitis; Dental Scaling; Female; Follow-Up Stu | 2016 |
Alendronate- and risedronate-induced acute polyarthritis.
Topics: Alendronate; Arthritis; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis, | 2016 |
Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Exercise; Female; Humans; Mid | 2016 |
Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
Topics: Aged; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Administration Schedule; Fem | 2017 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A | 2009 |
Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.
Topics: Aged; Biomarkers; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporos | 2008 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analys | 2008 |
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Femur; Fr | 2009 |
Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Collagen Type I; Diph | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?
Topics: Aged; Bone Density Conservation Agents; Canada; Decision Making; Epidemiologic Methods; Etidronic Ac | 2009 |
Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies.
Topics: Bone Density Conservation Agents; Calcium Compounds; Data Collection; Diphosphonates; Drug Combinati | 2009 |
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates | 2009 |
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidr | 2008 |
[Postmenopausal osteoporosis. Bisphosphonates are not all equal].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drugs, Gene | 2009 |
[Patient compliance program aids therapy success].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Clinical Trials as Topic; D | 2009 |
Risedronate on two consecutive days per month.
Topics: Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Humans; Medi | 2009 |
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Diseas | 2009 |
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Cost-Benefit Ana | 2010 |
[Acute exacerbation of a chronic esophagitis].
Topics: Acute Disease; Anti-Bacterial Agents; Bone Density Conservation Agents; Clindamycin; Diagnosis, Diff | 2009 |
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Topics: Aged; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Female; Humans; Model | 2010 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Meth | 2010 |
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggreg | 2010 |
Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
Topics: Aged; Aged, 80 and over; Binding, Competitive; Bone Density Conservation Agents; Diphosphonates; Eti | 2010 |
Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis.
Topics: Aged; Aorta, Abdominal; Atherosclerosis; Body Mass Index; Bone Density Conservation Agents; Calcinos | 2010 |
Risedronate-induced arthritis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoarthritis; Osteo | 2010 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bon | 2011 |
Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Asian People; Diphosphonates; Etidronic Acid; Female; Hip; Humans; Japan; Osteopo | 2011 |
When do bisphosphonates make the most sense?
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Re | 2011 |
Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.
Topics: Aged; Antioxidants; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Free Rad | 2012 |
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Densit | 2012 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosph | 2012 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Aged; Alendronate; Analysis of Variance; Bone and Bones; Bone Density; Bone Density Conservation Age | 2011 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian Peopl | 2012 |
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic | 2013 |
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation A | 2012 |
Low-dose risedronate sodium protects bone cells after abrupt oestrogen withdrawal.
Topics: Adipocytes; Alkaline Phosphatase; Animals; Apoptosis; Bone Density Conservation Agents; Cell Differe | 2012 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Co | 2013 |
[Osteoporosis therapy. A comparison of bisphosphonates].
Topics: Aged; Alendronate; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Random | 2002 |
Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Cause of Death; Clinical Trials, Phase III | 2002 |
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal | 2002 |
[Treatment of osteoporosis. Not only measurements count].
Topics: Biopsy; Bone and Bones; Bone Density; Clinical Trials as Topic; Etidronic Acid; Humans; Middle Aged; | 2002 |
Once-a-week risedronate (actonel).
Topics: Administration, Oral; Digestive System; Diphosphonates; Dose-Response Relationship, Drug; Drug Admin | 2002 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, | 2002 |
Medications for postmenopausal osteoporosis prevention.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated | 2002 |
[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].
Topics: Aged; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Spo | 2003 |
[Vertebral body fracture as incidental finding in thoracic radiography. Family physician usually does not learn about it].
Topics: Bone Density; Diphosphonates; Double-Blind Method; Etidronic Acid; Family Practice; Female; Follow-U | 2003 |
Bone density changes with once weekly risedronate in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium; Digestive System; Diphosphonates; Drug Tolerance; Et | 2003 |
Tolerability and compliance with risedronate in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Gastrointe | 2003 |
[For patients with osteoporosis-induced fracture the emergency brake must be pulled. Every 4th patient as a recurrence in the following year].
Topics: Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteop | 2003 |
[To treat effectively without delay. The data on fractures decisive].
Topics: Aged; Calcium Channel Blockers; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dipho | 2003 |
[Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years].
Topics: Aged; Bone Density; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Spontaneous; Humans | 2003 |
[Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Os | 2003 |
[Osteoporosis therapy. Bisphosphonates compared].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Etidronic | 2003 |
Efficacy of risedronate on clinical vertebral fractures within six months.
Topics: Body Height; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; R | 2004 |
Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Fema | 2003 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fr | 2004 |
[Risedronate affects bone strength, too. Faster protective effect on microarchitecture].
Topics: Bone and Bones; Calcium Channel Blockers; Collagen; Etidronic Acid; Female; Humans; Middle Aged; Ost | 2004 |
[Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].
Topics: Alendronate; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Multicenter | 2004 |
[Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractu | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic | 2004 |
[FACT study: benefits of alendronate].
Topics: Aged; Alendronate; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Fema | 2005 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporos | 2005 |
[Evaluation of the effects of treatment of osteoporosis].
Topics: Aged; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Etidronic Acid; Female | 2005 |
[Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
Topics: Alendronate; Calcitonin; Calcium; Clinical Trials as Topic; Cohort Studies; Drug Packaging; Etidroni | 2005 |
[Excellent adjustment with greater action. To pay attention to improving compliance].
Topics: Aged; Calcium; Clinical Trials as Topic; Cross-Over Studies; Diphosphonates; Drug Packaging; Drug Th | 2005 |
[Marketing--alendronate versus risedronate].
Topics: Alendronate; Bone Density; Drug Information Services; Etidronic Acid; Humans; Marketing; Osteoporosi | 2005 |
[To increase bone density faster and stronger].
Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter | 2005 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; | 2005 |
Hospitalization-related bone loss and the protective effect of risedronate.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Femur | 2006 |
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female | 2005 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Causality; Clinical Trials as Topic; Etidr | 2005 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; F | 2005 |
One drug tackles two diseases.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; | 2005 |
[What do we need to know--what can we do?].
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium Channel Blockers; C | 2005 |
Osteoporosis management in a Medicaid population after the Women's Health Initiative study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; | 2006 |
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Health Care Costs; Huma | 2006 |
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administr | 2006 |
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Dip | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic A | 2007 |
European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; E | 2006 |
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid | 2006 |
Risedronate-induced Hepatitis.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Chemical and Drug Induced Liver Injury; Dose-Re | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Ag | 2007 |
Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Topics: Absorptiometry, Photon; Aged; Biopsy; Bone and Bones; Bone Density Conservation Agents; Bone Remodel | 2007 |
[Men also need bone protection].
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; | 2006 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Fe | 2006 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Sp | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diph | 2007 |
Hip fractures in users of first- vs. second-generation bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonat | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Cost-B | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic | 2008 |
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Cohort Studies; Databases, Factual; Diphospho | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channe | 1995 |
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitoni | 1995 |
The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
Topics: Administration, Oral; Animals; Bone Density; Bone Development; Bone Diseases, Metabolic; Bone Remode | 1995 |
Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Estradiol; Etidronic Aci | 1995 |
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
Topics: Animals; Biomarkers; Bone Density; Bone Development; Bone Resorption; Calcitonin; Disease Models, An | 1995 |
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal | 1995 |
Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Osteoporosis, Po | 1998 |
Risedronic acid. NE 58095, risedronate sodium, Actonel.
Topics: Aged; Animals; Drugs, Investigational; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Os | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis | 1999 |
Conference report--scientific and clinical developments in osteoporosis.
Topics: Bone Density; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Estrogen Receptor beta; Est | 1999 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagoni | 2000 |
Once-a-week alendronate (Fosamax).
Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials a | 2001 |
The role of combination treatment for osteoporosis.
Topics: Aged; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bo | 2001 |
Absolute vs. relative numbers in evaluating drug therapy.
Topics: Alendronate; Data Interpretation, Statistical; Etidronic Acid; Female; Fractures, Bone; Humans; Info | 2001 |
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; | 2001 |
[Fluorides and bisphosphonates in the treatment of osteoporosis].
Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru | 2001 |
[Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
Topics: Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Follow-Up Stud | 2001 |
[Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].
Topics: Aged; Clinical Trials as Topic; Drug Approval; Etidronic Acid; Female; Femoral Neck Fractures; Fract | 2001 |
[Osteoporosis. Fracture as alarm signal].
Topics: Aged; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenop | 2001 |
A method to assess the proportion of treatment effect explained by a surrogate endpoint.
Topics: Biometry; Endpoint Determination; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Rand | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; H | 2001 |
[Therapy of osteoporosis. Risk factors alone are not an indication].
Topics: Aged; Aged, 80 and over; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Oste | 2001 |
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Topics: Aged; Calcium Channel Blockers; Cortisone; Costs and Cost Analysis; Double-Blind Method; Etidronic A | 2002 |
The cost utility of bisphosphonate treatment in established osteoporosis.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Female; Hip Fractures; Humans | 2002 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |